The European Union’s In Vitro Diagnostic Regulation (IVDR) has significantly reshaped the landscape of precision medicine development within the EU. Implemented to enhance the safety and reliability of in vitro diagnostic (IVD) devices, the IVDR introduces stringent requirements that have profound implications for stakeholders in the precision medicine sector. Lets discuss The Impact of IVDR […]
In a strategic move to revolutionize cell cultivation processes within the pharmaceutical and biotechnology sectors, Bürkert Fluid Control Systems has announced a significant investment in Green Elephant Biotech, a German startup renowned for its sustainable innovations in cell culture technology. This partnership aims to develop more efficient, flexible, and eco-friendly bioreactor systems, addressing the growing
Bürkert and Green Elephant Biotech Join Forces for a More Sustainable Biotech Industry Read More »
Nutrify Today is set to host the 4th Annual Global C-Suite Sumflex 2025 on May 8th and 9th at the Trident and Oberoi Hotels in Mumbai, India. This exclusive, invitation-only event will convene 400 global industry leaders, including executives from branded formulation and ingredient companies, esteemed medical doctors, dietitians, and investment bankers. The summit aims
C-Suite Sumflex 2025: Global Nutraceutical Leaders to Meet in Mumbai Read More »
Sun Pharmaceutical Industries Limited (Sun Pharma) has been honored by inclusion in the S&P Global Sustainability Yearbook 2025, ranking within the top 5% of pharmaceutical companies globally. This prestigious recognition underscores Sun Pharma’s unwavering commitment to Environmental, Social, and Governance (ESG) principles, reflecting its dedication to sustainable and responsible business practices. Sun Pharma Rises in
Sun Pharma Rises in Global Sustainability Rankings for 2025 Read More »
The integration of Generative Artificial Intelligence (GenAI) into India’s pharmaceutical sector is driving significant operational transformations, as highlighted in a recent report by EY. The study reveals that 50% of Indian pharmaceutical companies have initiated GenAI proof-of-concept projects, with 25% advancing to full-scale AI solution implementations. In the broader healthcare landscape, 66% of organizations are
How GenAI is Transforming Pharmaceutical Operations in India Read More »
Erectile Dysfunction (ED) is a prevalent condition affecting men worldwide, characterized by the consistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. This condition can significantly impact self-esteem, intimate relationships, and overall quality of life. Understanding the underlying causes, recognizing the symptoms, and exploring advanced treatment options are crucial steps toward
Understanding Erectile Dysfunction: Causes, Symptoms, and Advanced Treatment Options Read More »
The pharmaceutical sector has recently undergone a market correction, prompting investors to reassess the potential of pharma stocks. Elara Capital, a prominent financial services firm, views this downturn as a favorable entry point for long-term investors. The correction stems from various factors, including global market volatility and sector-specific challenges. Despite these hurdles, the pharmaceutical industry’s
Pharma Sector Correction: A Prime Opportunity for Long-Term Investors Read More »
In January 2025, President Donald Trump unveiled a comprehensive Health Care Strategy poised to significantly impact the pharmaceutical industry. Trump’s Health Care Strategy, characterized by deregulation and tax incentives, aims to stimulate innovation and reduce drug prices, potentially reshaping the landscape for pharmaceutical companies. Deregulation to Foster Innovation A cornerstone of President Trump’s Health Care
Trump’s Health Care Strategy: Implications for Drug Manufacturers Read More »
President Donald Trump’s recent imposition of tariffs on pharmaceutical imports from China, Mexico, and Canada has raised concerns about potential impacts on the U.S. drug market. However, analyses suggest that brand-name drug manufacturers are likely to experience minimal effects, while generic drugmakers may face significant challenges. Impact on Brand-Name Drug Manufacturers Brand-name pharmaceutical companies often
How Trump’s New Tariffs Affect the Pharmaceutical Industry Read More »
In a strategic move to enhance cancer treatment options in the United States, Zydus Lifesciences has entered into an exclusive licensing, supply, and commercialization agreement with Zhuhai Beihai Biotech Co. This partnership focuses on the U.S. commercialization of BEIZRAY (Albumin Solubilized Docetaxel Injection), a novel formulation designed to improve therapeutic outcomes for cancer patients. Zydus
